ES2573931T3 - Nuevos polimorfismos de clorhidrato de erlotinib y método de preparación - Google Patents

Nuevos polimorfismos de clorhidrato de erlotinib y método de preparación Download PDF

Info

Publication number
ES2573931T3
ES2573931T3 ES07827567.4T ES07827567T ES2573931T3 ES 2573931 T3 ES2573931 T3 ES 2573931T3 ES 07827567 T ES07827567 T ES 07827567T ES 2573931 T3 ES2573931 T3 ES 2573931T3
Authority
ES
Spain
Prior art keywords
preparation
polymorphisms
new
erlotinib hydrochloride
methoxyethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07827567.4T
Other languages
English (en)
Inventor
Ramanadham Jyothi Prasad
Bhujanga Rao Adibhatla Kali Satya
Nannapaneni Venkaiah Chowdary
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Natco Pharma Ltd
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Application granted granted Critical
Publication of ES2573931T3 publication Critical patent/ES2573931T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Proceso para la elaboración de un polimorfo cristalino Forma P de sal clorhidrato de N-(3-etinilfenil)-6,7-bis(2- metoxietoxi)-4-quinazolinamina, proceso que comprende: disolver N-(3-etinilfenil)-6,7-bis(2-metoxietoxi)-4-quinazolinamina en cloruro de metileno seco; y hacerlo reaccionar con una solución de gas de cloruro de hidrógeno en isopropanol

Description

imagen1
imagen2
imagen3

Claims (1)

  1. imagen1
ES07827567.4T 2007-02-21 2007-09-11 Nuevos polimorfismos de clorhidrato de erlotinib y método de preparación Active ES2573931T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN349CH2007 2007-02-21
INCH03492007 2007-02-21
PCT/IN2007/000407 WO2008102369A1 (en) 2007-02-21 2007-09-11 Novel polymorphs of erlotinib hydrochloride and method of preparation

Publications (1)

Publication Number Publication Date
ES2573931T3 true ES2573931T3 (es) 2016-06-13

Family

ID=38952058

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07827567.4T Active ES2573931T3 (es) 2007-02-21 2007-09-11 Nuevos polimorfismos de clorhidrato de erlotinib y método de preparación

Country Status (6)

Country Link
US (2) US8349855B2 (es)
EP (1) EP2170844B1 (es)
KR (1) KR20100014512A (es)
ES (1) ES2573931T3 (es)
PT (1) PT2170844T (es)
WO (1) WO2008102369A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009025875A1 (en) * 2007-08-23 2009-02-26 Plus Chemicals Sa Stable formulations of crystalline erlotinib hcl
WO2010040212A1 (en) * 2008-10-08 2010-04-15 Apotex Pharmachem Inc. Processes for the preparation of erlotinib hydrochloride
EP2213281A1 (en) * 2009-02-02 2010-08-04 Ratiopharm GmbH Pharmaceutical composition comprising N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
WO2010109443A1 (en) 2009-03-26 2010-09-30 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
WO2011058525A2 (en) 2009-11-12 2011-05-19 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
AU2011298167B2 (en) 2010-07-23 2015-11-26 Generics [Uk] Limited Pure erlotinib
CN101948441B (zh) * 2010-09-07 2012-07-25 江苏先声药物研究有限公司 一种Erlotinib盐酸盐A晶型的制备方法
WO2012150606A2 (en) 2011-05-03 2012-11-08 Cadila Healthcare Limited A process for preparing stable polymophic form of erlotinib hydrochloride
US9593083B2 (en) 2012-09-04 2017-03-14 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
CN103333124B (zh) * 2013-05-28 2015-03-25 埃斯特维华义制药有限公司 一种制备盐酸厄洛替尼晶型f的方法
CN103333125B (zh) * 2013-06-19 2015-11-11 扬子江药业集团有限公司 一种喹唑啉胺盐酸盐稳定多晶型物的制备方法
CN103435559B (zh) * 2013-07-03 2015-05-13 山东金城医药化工股份有限公司 盐酸厄洛替尼新晶型及其制备方法
KR102802129B1 (ko) * 2018-09-14 2025-05-02 한미약품 주식회사 퀴나졸린 화합물 및 이의 염산염의 결정 형태
JP7212787B2 (ja) * 2019-01-09 2023-01-25 ピュラック バイオケム ビー． ブイ． Ｐｌａベースの物品の熱成形

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE446955T1 (de) 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
YU13200A (sh) 1999-03-31 2002-10-18 Pfizer Products Inc. Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7148231B2 (en) 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
WO2007060691A2 (en) * 2005-11-23 2007-05-31 Natco Pharma Limited A novel process for the preparation of erlotinib
WO2007138613A2 (en) 2006-05-25 2007-12-06 Vittal Mallya Scientific Research Foundation A process for synthesis of [6,7-bis-(2-methoxyethoxy)-quinazolin-4-yl]-(3-ethynylphenyl)amine hydrochloride

Also Published As

Publication number Publication date
KR20100014512A (ko) 2010-02-10
US20130131341A1 (en) 2013-05-23
WO2008102369A1 (en) 2008-08-28
US8748602B2 (en) 2014-06-10
EP2170844A1 (en) 2010-04-07
EP2170844B1 (en) 2016-05-04
PT2170844T (pt) 2016-08-05
US8349855B2 (en) 2013-01-08
US20100261738A1 (en) 2010-10-14

Similar Documents

Publication Publication Date Title
BRPI0716009A2 (pt) Aparelho e processo para produção de etanol
BRPI0907909A2 (pt) Sistema, e, processo para a produção e uso do mesmo
BRPI0817154A2 (pt) "método de modificar uma célula de levedura para a produção de etanol, célula de levedura modificada, uso de uma célula de levedura modificada e método para a produção de etanol"
ES2525918T3 (es) Proceso para la fabricación de Nicorandil
BRPI0914822A2 (pt) processo, e, sistema para a produção de gás de síntese
TWI367259B (en) A method for the detection of chromosomal aneuploidies
EP2022834A4 (en) NITROGENIC ALLOY AND THEIR USE FOR THE PREPARATION OF PHOSPHORUS
SI1981863T1 (sl) Postopek za pripravo aminokrotonilamino-substituiranih kinazolinskih derivatov
EP2163595A4 (en) FLUORESCENT, MANUFACTURING METHOD AND LIGHTING DEVICE THEREOF
FR2913073B1 (fr) Carter de compresseur en matiere synthetique, et procede pour sa fabrication
DE602005012190D1 (de) Träger , Entwickler, Bildherstellungsverfahren und Arbeitseinheit
BRPI0822459A2 (pt) Sistema e processo para a obtenção de biodiesel a partir de algas
BRPI0814586A2 (pt) Método e aparelho para monitorar contaminações offshore
FI20055416A0 (fi) Bioabsorvoituva nauhajärjestelmä, bioabsorboituva nauha, menetelmä bioabsorboituvan nauhan valmistamiseksi, bioabsorboituvan nauhan neulajärjestelmä sekä lukitusmekanismi
IL204516A (en) Organic Reliable Salt of 6 - Fluoro - 3 - Hydroxy - 2 - Pyrazinecarbonitrile and a method for its production
FR2866070B1 (fr) Turboreacteur a fort taux de dilution
FR2908327B1 (fr) Procede de fabrication de clinker a emission de co2 controlee
IL184798A0 (en) Quinazoline derivatives as tyrosine kinase inhibitors
BRPI0817737A2 (pt) Método de produção de estoque de base de combustível diesel e estoque de base de combustível diesel do mesmo
EP1992612A4 (en) 1-FLUOR-1,1-BIS (PHENYLSULFONYL) METHANE AND METHOD FOR THE PRODUCTION THEREOF
FI20065121A0 (fi) Menetelmä selluloosapohjaisten tekstiilimateriaalien esikäsittelemiseksi
EP2371928A4 (en) METHOD FOR PRODUCING AN M-C-N-O-BASED FLUORATE
BRPI0815899A2 (pt) Instalação e processo para solda
BRPI0915764A2 (pt) enrijecedor inclinado e aparelho e método para formar o mesmo
BRPI0717466A2 (pt) Quelatos metálicos contendo um grupo peg perfluorado, processo para sua produção e seu uso.